Tocilizumab administration in a refractory case of COVID-19

被引：11
|
作者：
Dastan, Farzaneh [1 ,2 ]
Nadji, Seyed Alireza [3 ]
Saffaei, Ali [4 ]
Tabarsi, Payam [5 ]
机构：
[1] Shahid Beheshti Univ Med Sci, Dept Clin Pharm, Tehran, Iran
[2] Shahid Beheshti Univ Med Sci, Natl Res Inst TB & Lung Dis NRITLD, Chron Resp Dis Res Ctr CRDRC, Tehran, Iran
[3] Shahid Beheshti Univ Med Sci, Virol Res Ctr, Natl Inst TB & Lung Dis NRITLD, Tehran, Iran
[4] Shahid Beheshti Univ Med Sci, Sch Pharm, Dept Clin Pharm, Student Res Comm, Tehran, Iran
[5] Shahid Beheshti Univ Med Sci, Natl Res Inst TB & Lung Dis NRITLD, Clin TB & Epidemiol Res Ctr, Daarabad St,Niyavaran St, Tehran 1956944413, Iran
来源：
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS | 2020年 / 56卷 / 02期
关键词：
D O I：
10.1016/j.ijantimicag.2020.106043
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Tocilizumab and COVID-19: Timing of Administration and Efficacy
    Abidi, Emna
    El Nekidy, Wasim S.
    Alefishat, Eman
    Rahman, Nadeem
    Petroianu, Georg A.
    El-Lababidi, Rania
    Mallat, Jihad
    [J]. FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [2] BRADYCARDIA FOLLOWING TOCILIZUMAB ADMINISTRATION FOR COVID-19
    Staubs, Amanda
    Noori, Feroz
    Houshmand, Farnaz
    [J]. CRITICAL CARE MEDICINE, 2022, 50 (01) : 69 - 69
  • [3] Tocilizumab and COVID-19: Timing of administration assessment
    Richier, Q.
    Jachiet, V
    Bonnemains, V
    Placais, L.
    Abisror, N.
    Garnier, M.
    Pacanowski, J.
    Dhote, R.
    Hinchschberger, O.
    Michel, M.
    Bienvenu, B.
    Comarmond, C.
    Lacombe, K.
    Mekinian, A.
    [J]. INFECTIOUS DISEASES NOW, 2022, 52 (01): : 31 - 34
  • [4] Impact of tocilizumab administration on mortality in severe COVID-19
    Andrew Tsai
    Oumou Diawara
    Ronald G. Nahass
    Luigi Brunetti
    [J]. Scientific Reports, 10
  • [5] Impact of tocilizumab administration on mortality in severe COVID-19
    Tsai, Andrew
    Diawara, Oumou
    Nahass, Ronald G.
    Brunetti, Luigi
    [J]. SCIENTIFIC REPORTS, 2020, 10 (01)
  • [6] Ruxolitinib for tocilizumab-refractory severe COVID-19 infection
    Innes, Andrew J.
    Cook, Lucy B.
    Marks, Sasha
    Bataillard, Edward
    Crossette-Thambiah, Christina
    Sivasubramaniam, Gayathiri
    Apperley, Jane
    Milojkovic, Dragana
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2020, 190 (04) : E198 - E200
  • [7] High levels of TNFα in patients with COVID-19 refractory to tocilizumab
    Danlos, F. X.
    Ackermann, F.
    Rohmer, J.
    Roumier, M.
    Marabelle, A.
    Michot, J. M.
    [J]. EUROPEAN JOURNAL OF CANCER, 2021, 149 : 102 - 104
  • [8] Tocilizumab and COVID-19
    Chaudhry, Dhruva
    Singh, Pawan K.
    [J]. INDIAN JOURNAL OF CRITICAL CARE MEDICINE, 2020, 24 (09) : 741 - 743
  • [9] Tocilizumab in Covid-19
    Leaf, David E.
    Gupta, Shruti
    Wang, Wei
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (01): : 86 - 87
  • [10] The effect of tocilizumab administration on inflammatory markers in COVID-19 patients
    Soliman, Engy Mohamed Riyad
    Wageh, Khaled Mohamed
    Mohamed, Mahmoud Mokhtar
    Mohamed, Hoda Attiatullah
    [J]. EGYPTIAN JOURNAL OF BRONCHOLOGY, 2024, 18 (01)
12345